RxDoctor Payments Data

David Nitti, MD

Internal Medicine · Hawthorne, NJNPI 1750499158

Payments from drug & device makers

$339in general payments, 2019–2025

Across 19 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Centinel Spine, LLC$67
  • AstraZeneca$56
  • GSK$47
  • Otsuka America Pharmaceutical, Inc.$45
  • Novo Nordisk$30
  • Sunovion Pharmaceuticals Inc.$18
  • plus $77 from 6 others

What the payments were for

  • Food & beverage$339100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$339 in reported general payments places this provider in the 45th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$209,626
Medicare patients
439
Services billed
2,439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban154$139,724
RybelsusSemaglutide44$69,332
FarxigaDapagliflozin Propanediol40$49,720
JardianceEmpagliflozin39$38,878
XifaxanRifaximin11$37,742
XareltoRivaroxaban28$28,805
JanumetSitagliptin Phos/Metformin Hcl16$25,341
JanuviaSitagliptin Phosphate21$16,666
RestasisCyclosporine25$16,186
MyrbetriqMirabegron20$13,290
Breo ElliptaFluticasone/Vilanterol29$11,389
NamzaricMemantine Hcl/Donepezil Hcl13$7,781
RytaryCarbidopa/Levodopa11$6,226
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,906
Atorvastatin Calcium544$5,881

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$30$69,33244 claims
AstraZenecaFarxiga$56$49,72040 claims
AbbVieRestasis, Namzaric, Combigan$12$26,81351 claims
GSKBreo Ellipta, Anoro Ellipta$47$17,29541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Hawthorne

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →